Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of JLP-2004 vs JC-013 in Healthy Volunteers
NCT06169059Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of JLP-2004 in osteoarthritis (OA), rheumatoid arthritis (RA) and back pain (2 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 24 hours and Maximum Plasma Concentration at 24 hours. Started Oct 2023; status: completed.
02
Drugs
JLP-2004
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)back pain
Beyond the preview
Go deeper on NCT06169059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169059.